Eur Rev Med Pharmacol Sci 2020; 24 (3): 1062-1071
DOI: 10.26355/eurrev_202002_20156

MiRNA-584 suppresses the progression of ovarian cancer by negatively regulating LPIN1

L. Yang, H.-L. Ma

Department of Gynecology, Zhoukou Central Hospital of Henan Province, Zhoukou, China. honglong6661@163.com


OBJECTIVE: The aim of the study was to detect the expression level of microRNA-584 (miRNA-584) in ovarian cancer (OCa) and to elucidate its regulatory effect on OCa progression by regulating LPIN1.

PATIENTS AND METHODS: Expression levels of miRNA-584 and LPIN1 in 31 matched OCa tissues and paracancerous tissues were detected. The relationship of miRNA-584 level with clinical indicators and prognosis of OCa patients was analyzed. Influences of miRNA-584/LPIN1 regulatory loop on malignant phenotypes of OVCAR3 and PEO1 cells were assessed. In addition, the interaction between miRNA-584 and LPIN1 was confirmed by Dual-Luciferase reporter gene assay and rescue experiments.

RESULTS: MiRNA-584 was lowly expressed in OCa tissues, while LPIN1 was highly expressed. OCa patients expressing a low level of miRNA-584 suffered from higher rates of lymphatic metastasis and distant metastasis, as well as worse survival. The overexpression of miRNA-584 in OVCAR3 cells attenuated proliferative and migratory abilities, while the knockdown of miRNA-584 in PEO1 cells yielded the opposite results. LPIN1 was verified to be the target binding to miRNA-584 and its level was negatively regulated by miRNA-584. The overexpression of LPIN1 accelerated OCa cells to proliferate and migrate. Importantly, LPIN1 was responsible for OCa progression regulated by miRNA-584.

CONCLUSIONS: MiRNA-584 is downregulated in OCa tissues and cell lines. MiRNA-584 level is correlated with lymphatic metastasis, distant metastasis, and poor prognosis in OCa patients. By negatively regulating LPIN1, miRNA-584 suppresses the malignant progression of OCa.

Free PDF Download

To cite this article

L. Yang, H.-L. Ma
MiRNA-584 suppresses the progression of ovarian cancer by negatively regulating LPIN1

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 3
Pages: 1062-1071
DOI: 10.26355/eurrev_202002_20156